A detailed history of Price T Rowe Associates Inc transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,958,079 shares of CNTA stock, worth $26.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,958,079
Previous 2,539,464 16.48%
Holding current value
$26.7 Million
Previous $20.2 Million 65.36%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$6.73 - $12.2 $2.82 Million - $5.11 Million
418,615 Added 16.48%
2,958,079 $33.4 Million
Q4 2023

Feb 14, 2024

SELL
$5.52 - $8.03 $53,378 - $77,650
-9,670 Reduced 0.38%
2,539,464 $20.2 Million
Q3 2023

Nov 14, 2023

BUY
$6.01 - $8.24 $1.12 Million - $1.53 Million
185,923 Added 7.87%
2,549,134 $16.5 Million
Q2 2023

Aug 14, 2023

BUY
$3.68 - $6.9 $183,183 - $343,468
49,778 Added 2.15%
2,363,211 $14.6 Million
Q1 2023

May 15, 2023

SELL
$3.03 - $4.0 $223,414 - $294,936
-73,734 Reduced 3.09%
2,313,433 $8.91 Million
Q4 2022

Feb 14, 2023

SELL
$3.05 - $4.19 $179,388 - $246,439
-58,816 Reduced 2.4%
2,387,167 $7.4 Million
Q3 2022

Nov 14, 2022

SELL
$3.8 - $5.91 $57,558 - $89,518
-15,147 Reduced 0.62%
2,445,983 $9.83 Million
Q2 2022

Aug 15, 2022

SELL
$3.18 - $9.85 $214,500 - $664,412
-67,453 Reduced 2.67%
2,461,130 $12 Million
Q1 2022

May 16, 2022

BUY
$7.45 - $11.59 $3.37 Million - $5.24 Million
451,813 Added 21.76%
2,528,583 $22.7 Million
Q4 2021

Feb 14, 2022

BUY
$10.99 - $17.54 $647,278 - $1.03 Million
58,897 Added 2.92%
2,076,770 $23.4 Million
Q3 2021

Nov 15, 2021

BUY
$16.7 - $23.11 $113,560 - $157,148
6,800 Added 0.34%
2,017,873 $33.1 Million
Q2 2021

Aug 16, 2021

BUY
$21.71 - $25.66 $43.7 Million - $51.6 Million
2,011,073 New
2,011,073 $43.9 Million

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $852M
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.